Abstract
Introduction
According to a 2011 report [1] , more than 500 million adults worldwide were recognized as obese. Obesity is a major concern because it represents an important risk factor for diabetes, hypertension and cardiovascular diseases. The impact of obesity on cancer survival has been also noted. Renehan et al. reported that an increase in body mass index is a risk factor for some cancers, including esophageal adenocarcinoma and thyroid cancers [2] . The systemic pharmacological effect of adipokines secreted by adipocytes as well as increased insulin levels are major mechanisms of obesity in cancer development.
In addition, cancer-associated adipocytes (CAAs) play an important role in tumor progression [3, 4] , as was indicated by in vitro and in vivo evidence showing that CAAs promote tumor cell survival, proliferation, differentiation and migration [4, 5] . Although the detailed mechanisms are not fully elucidated, the interaction of CAAs with tumor cells seems to depend on biologically active substances such as interleukin 6 (IL-6) and free fatty acids [4] .
Fatty acid binding proteins (FABPs) regulate lipid responses in cells and are involved
in metabolic and inflammatory pathways [6] . Through the transportation of lipids to specific cell components, FABPs regulate lipid usage in cells for storage, signaling and transcriptional regulation. Among the FABPs, FABP4 is the best-characterized isoform and is predominantly expressed in adipocytes and macrophages [6] . FABP4 regulates the activities of Jun N-terminal kinase (JNK) 1 to enhance production of cytokines such as tumor necrosis factor α (TNF-α), IL-1β, and monocyte chemoattractant protein 1 (MCP-1) [7, 8] . CAAs were recently reported to interact metabolically with cancer cells through the transport of free fatty acids on the cellular boundary, and this interaction could be inhibited by treatment of cells with a FABP4 selective inhibitor [5] . Furthermore, tumor proliferation and metastasis were significantly diminished in FABP4-knockout mice [5] , indicating an important role for FABP4 in the metabolic interaction between CAAs and cancer cells as well as in tumor progression. Therefore, given the promise of FABP4 as a therapeutic target in such tumors, in vivo noninvasive imaging techniques are urgently needed for the development of therapeutic agents that target FABP4 and also to evaluate the functions of FABP4 in tumors.
We recently developed a FABP4 imaging probe, [ 123/125 I]TAP1, for use in nuclear imaging with single photon emission computed tomography (SPECT) [9] . Although the design of [ 123/125 I]TAP1 was based on the structures of selective FABP4 inhibitors and showed high affinity and selectivity for FABP4, this probe had high lipophilicity that caused significant nonspecific distribution in vivo. This lipophilicity was considered to be a limitation of this probe that required improvement before it could be used in 
Materials and Methods

General
All reagents were purchased from Nacalai Tesque, Inc. and Wakenyaku Co., Ltd., and were used without further purification unless otherwise noted. High resolution mass spectra (HRMS) were acquired on a JMS-SX 102A QQ or JMS-GC-mate mass spectrometer (JEOL). Recombinant hexahistidine (his)-tagged FABP3, FABP4 and FABP5 proteins were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). All PET scans were obtained on a small-animal scanner (FX3300 imager; SII NanoTechnology Inc., Northridge, CA, USA).
Animals & Cells
Animal experiments were conducted in accordance with our institutional guidelines supplemented with 10% heat-inactivated FBS, 50 U/ml penicillin and 50 μg/ml streptomycin at 37 °C in 5% CO2. Differentiation of 3T3-L1 cells was performed as described previously [10] . Briefly, 2 days after confluence was reached, the medium was replaced with DMEM containing 10% FBS and inducers (0.25 mM dexamethasone, 10 μg/ml insulin, 0.5 mM 3-isobutyl-1-methylxanthine and 10 μM pioglitazone hydrochloride) for 2 days. The medium was then changed to DMEM supplemented with 10% FBS, 10 μg/ml insulin and 10 μM pioglitazone hydrochloride, and then incubated for 2 days. The medium was then changed every other day with DMEM supplemented with 10% FBS and 10 μM pioglitazone hydrochloride. After 8-10 days, the differentiated adipocytes were confirmed by western blotting and Oil red O staining following our previous studies [9, 10] and used for experiments.
Chemistry
Nonradioactive FTAP1, nonradioactive FTAP3, and FTAP1 precursors were synthesized as shown in Fig. 1 . In each step in general, the solvent was evaporated under reduced pressure after the reaction, water was added, and the product was extracted into ethyl acetate. After the organic layer was dried over Na2SO4 and filtered, the solvent was evaporated and the residue was purified by silica gel chromatography. [1, 2, 4] triazolo [1,5-a] 
5-(Chloromethyl)-2-phenyl-
pyrimidin-7(4H)-one (1)
Compound 1 was synthesized according to previously reported procedures [11] .
1-(Benzyloxy)-3-(2-fluoroethoxy)benzene (2)
3-Benzyloxyphenol (0.9 g, 4.6 mmol) and 2-fluoroethyl 4-methylbenzenesulfonate ( 
1-(Benzyloxy)-3-[2-{2-(2-fluoroethoxy)ethoxy}ethoxy]benzene (5)
3
5-[[3-[2-{2-(2-Fluoroethoxy)ethoxy)ethoxy}phenoxy]methyl]-2-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one (6)
2-{3-(Benzyloxy)phenoxy}ethanol (7)
3-Benzyloxyphenol (2.0 g, 10 mmol) and ethylene bromohydrin (3.8 g, 30 mmol)
were reacted overnight in the presence of K2CO3 (4. 
3-[2{(tert-Butyldimethylsilyl)oxy}ethoxy]phenol (8)
Tert-butyldimethylsilyl chloride (1.7 g, 11.2 mmol) and imidazole (1.0 g, 15 mmol)
were added to 7 (1.7 g, 7.0 mmol) in CH2Cl2 (20 ml) at 4 °C. The mixture was stirred at room temperature for 5 hr. Silica gel chromatography (ethyl acetate/hexane = 1/15) was performed. Then, the recovered sample (2.3 g, 6.5 mmol) and palladium carbon (Pd 10%, 0.2 g) was stirred in methanol (50 ml) at room temperature for 3 hr under a hydrogen atmosphere. After filtration, the solvent was evaporated and purified by silica gel chromatography (ethyl acetate/hexane = 1/8) to yield 8 (1.7 g, 6.3 mmol, 88 % yield). (9) 1 (0.6 g, 2.5 mmol) and 8 (1.0 g, 3.7 mmol) were reacted for 6 hr in the presence of 
5-[{3-(2-Hydroxyethoxy)phenoxy}methyl]-2-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one
In vitro evaluation of nonradioactive compounds
The binding affinity of FTAP1 and FTAP3 for FABP4 was measured by competitive binding experiments using 8-anilino-1-naphthalene sulfonic acid (1,8-ANS) as the tracer [12] . Briefly, a mixture containing 0.12 ml phosphate buffer (50 mM, pH = 7.4), 0.03 ml The membrane permeability of FTAP1 and FTAP3 was measured using a pre-coated parallel artificial membrane permeation assay (PAMPA) plate system (BD Biosciences)
following the manufacturer's procedures. Briefly, the test compounds (100-200 μM, 0.2 ml) were added to the donor plate and PBS (-) (0.2 ml) was added to the acceptor plate in the PAMPA plate assembly. After coupling both plates together and incubating at room respectively. S is the membrane area and t is the incubation time. 
Radiosynthesis of [ 18 F]FTAP1
In vitro evaluation of [ 18 F]FTAP1
For protein immobilization, his-tagged FABP3 (0.75 mg/ml, 0.003 ml, 1. Aliquots from the 1-octanol and buffer phases (0.5 ml) were counted with a well-type γ-counter. This procedure was repeated three times. The partition coefficient was calculated from the ratio of radioactivity in the organic and aqueous layers.
The in vitro stability of [ 18 F]FTAP1 in plasma was measured using plasma samples taken from ddY mice (males, 7 weeks old). After addition of 0.01 ml [ 18 F]FTAP1 (0.08
MBq, 5% DMSO, v/v) to 0.1 ml plasma, the mixture was incubated at 37 °C for 2 hr.
After addition of 0.2 ml methanol and vortexing, the mixture was centrifuged (4,160 x g, with hematoxylin counterstaining performed as described in our previous report [9] . A FABP4-specific polyclonal rabbit IgG (ab13979, Abcam) and a perilipin-specific monoclonal rabbit IgG (D1D8, Cell Signaling) were used as the primary antibodies.
Antibodies from the Dako Envision + kit (K4002, Dako) were used as secondary antibodies for both primary antibodies. Subclass-matched irrelevant IgG served as a negative control.
Dynamic small-animal PET/computed tomography (CT) scans were performed with 
Statistical analysis
The Ki values are expressed as mean ± standard errors of the means (SEM), while the other data are expressed as mean ± SD. Statistical analysis was performed with the MannWhitney U test. P values < 0.05 were considered statistically significant.
Results
In vitro evaluation of nonradioactive compounds and radiosynthesis
A competitive binding assay using the established FABP4 ligand, 1,8-ANS, revealed the affinity of FTAP1 and FTAP3 for FABP4. Analysis of inhibition curves allowed determination of Ki values of 68 ± 8.9 and 490 ± 41 nM for FTAP1 and FTAP3, respectively. The membrane permeability determined by a PAMPA plate system was 1.5 ± 0.3 x 10 -6 and 0.18 ± 0.08 x 10 -6 cm/s for FTAP1 and FTAP3, respectively.
Based on the results of these evaluations, FTAP1 was chosen for further experiments.
[ 18 F]FTAP1 was successfully synthesized following the scheme shown in Fig. 2 . The radiochemical yield was 31 ± 17%, and the radiochemical purity was above 98% after purification by RP-HPLC.
In vitro evaluation of [ 18 F]FTAP1
The selectivity assay of [ 18 F]FTAP1 binding to FABP4 compared with that to FABP3
and FABP5 (Fig. 3) (Fig. 4) . Cell differentiation and FABP4 expression in differentiated adipocytes were confirmed by Oil red O staining and western blot analysis, respectively, in a similar way to that described in our previous report [9] . [ 18 F]FTAP1 showed significantly higher radioactivity in adipocytes than 3T3-L1 preadipocytes. Furthermore, the radioactivity accumulation in adipocytes was significantly and dose-dependently inhibited by treatment with the FABP4-specific inhibitor BMS309403, which at 10 μM inhibited almost all (ca. 95%) of the total probe uptake.
The partition coefficient (a logP value) of [ 18 F]FTAP1 was estimated to be 1.7 ± 0.04.
Over 95% of radioactivity was observed in an intact form by HPLC analysis after 2 hr incubation in mouse plasma at 37 °C, which indicates the high stability of
The percentage of [ 18 F]FTAP1 bound to serum proteins was found to be more than 99%. Ex vivo autoradiographic analysis (Fig. 6A) profile essentially corresponded to FABP4-positive areas ( Fig. 6A and B, black arrow).
In vivo and ex vivo evaluations of [ 18 F]FTAP1
The expression of perilipin, an adipocyte marker, was also confirmed in FABP4-positive areas (Fig. 6C) .
Finally, PET/CT imaging of tumor-bearing mice was performed 3 hr after
As shown in Fig. 7 , the tumor in the right hind legs was visualized, while the bladder exhibited high radioactivity due to probe excretion.
Discussion
In the present study we developed [ 18 F]FTAP1 for in vivo PET imaging of FABP4, which is closely related to CAA functions [5] , tumor progression [5] , and atherosclerotic plaque instability [13] . This probe is based on our previous radioiodinated probe, Recently, the role of CAA in tumor progression has been gathering attention. Nieman et al. [5] reported that CAAs metabolically interact with SKOV3ip1 cells and promote fatty acid metabolism in these cells that is required for proliferation. They also revealed that this interaction could be inhibited by a FABP4 inhibitor, and that the expression of FABP4 in tumor cells in the boundary areas between tumor cells and CAAs is enhanced.
Thus, FABP4 could be a key participant in the metabolic interaction between these cells.
Different tumor cells have been reported to express varying levels of FABP4, while some lack this protein [16] [17] [18] . Since FABP4 is not expressed in C6 cells in vitro [9] [17, 18] . FABP4 expressed in macrophages is also reported to correlate with instability of atherosclerotic plaques [13] . Thus, FABP4 imaging could be useful not only for evaluating the detailed functions of FABP4 in multiple settings and for the development of therapeutic agents that target FABP4, but also for assessing the pathophysiological grades of related diseases.
In conclusion, we developed a novel radiofluorinated probe, 
